Synedgen uses the science of glycomics – the study of complex sugar structure and function – to discover and develop ultra-purified therapeutic polysaccharides that are soluble, active, and targeted in the human body. These new molecular entities are designed to alter the progression of diseases that currently have limited treatment options, and improve the lives of patients.
See our lead program focused on controlling bacterial dysbiosis and GI inflammation
Learn how our drugs work at the mucosal interface
Partner with us to develop breakthrough therapeutics